Malaria treatment. Pediatric doses.
Reading File
Finding Sources
Searching the Web
pediatric malaria treatment WHO guidelines 2025 doses children
Searching PubMed
"malaria" AND "pediatric" AND "treatment"
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full response.
Malaria Treatment - Pediatric Doses
Note: Always check current WHO guidelines and your national/regional drug policy, as recommendations change with resistance patterns. Consult an ID specialist for severe or imported cases. Tetracyclines (doxycycline) are contraindicated in children <8 years; use clindamycin instead.
1. Uncomplicated P. falciparum Malaria
First-line: Artemisinin-Based Combination Therapies (ACT)
A. Artemether-Lumefantrine (Coartem®)
Each tablet: artemether 20 mg + lumefantrine 120 mg
Schedule: initial dose, second dose 8 h later, then twice daily for 2 more days (6 doses total over 3 days)
| Weight | Dose per administration |
|---|---|
| 5-15 kg | 1 tablet |
| 15-25 kg | 2 tablets |
| 25-35 kg | 3 tablets |
| >35 kg | 4 tablets (adult dose) |
- Not for children <5 kg. Take with food/fatty drink. - Tintinalli's Emergency Medicine, p. 1102; Goodman & Gilman's, p. 1318
B. Artesunate-Amodiaquine (ASAQ) (not available in US; common in Africa)
Once daily × 3 days
| Weight | Dose/day |
|---|---|
| 5 to <9 kg | 1 tablet of AS 25 mg/AQ 67.5 mg |
| 9 to <18 kg | 1 tablet of AS 50 mg/AQ 135 mg |
| 18 to <36 kg | 1 tablet of AS 100 mg/AQ 270 mg |
| ≥36 kg | 2 tablets of AS 100 mg/AQ 270 mg |
C. Artesunate-Sulfadoxine-Pyrimethamine (ACT-SP) (India national program)
Artesunate 4 mg/kg/day × 3 days + SP on day 1 + Primaquine 0.75 mg/kg on day 2
| Age (color pack) | Artesunate | SP |
|---|---|---|
| 0-1 yr (pink) | 25 mg | 250+12.5 mg (half tablet) |
| 1-4 yr (yellow) | 50 mg | 500+25 mg |
| 5-8 yr (green) | 100 mg | 750+37.5 mg |
| 9-14 yr (red) | 150 mg | 2 tablets SP |
| ≥15 yr (white) | 200 mg | Adult dose |
- Park's Textbook of Preventive and Social Medicine, p. 309
Alternative to ACT (when ACT not available)
Atovaquone-Proguanil (Malarone®)
(Adult tablet: atovaquone 250 mg + proguanil 100 mg; Pediatric tablet: 62.5 mg + 25 mg)
Once daily × 3 days
| Weight | Dose |
|---|---|
| 5-8 kg | 2 pediatric tablets/day |
| 9-10 kg | 3 pediatric tablets/day |
| 11-20 kg | 1 adult tablet/day |
| 21-30 kg | 2 adult tablets/day |
| 31-40 kg | 3 adult tablets/day |
| >41 kg | 4 adult tablets/day (adult dose) |
- Not for <5 kg. Do not use if already on atovaquone-proguanil prophylaxis. - Goodman & Gilman's, p. 1318
Quinine Sulfate + partner drug (backup)
| Drug | Pediatric Dose | Duration |
|---|---|---|
| Quinine sulfate | 10 mg/kg PO every 8 h | 3-7 days |
| + Doxycycline (≥8 yr only) | 2.2 mg/kg PO every 12 h (max 100 mg) | 7 days |
| OR + Clindamycin (<8 yr) | 7 mg/kg PO every 8 h | 7 days |
- Tintinalli's Emergency Medicine, p. 1102
2. Uncomplicated P. vivax / P. ovale Malaria (Chloroquine-Sensitive Areas)
Chloroquine 25 mg/kg total over 3 days (as base):
- Day 1: 10 mg/kg
- Day 2: 10 mg/kg
- Day 3: 5 mg/kg
Dosage chart (CQ 150 mg base tabs, PQ 2.5 mg tabs):
| Age | Day 1 CQ | Day 2 CQ | Day 3 CQ | PQ (Days 1-14) |
|---|---|---|---|---|
| <1 year | ½ tab | ½ tab | ¼ tab | 0 (contraindicated) |
| 1-4 years | 1 tab | 1 tab | ½ tab | 1 tab/day |
| 5-8 years | 2 tabs | 2 tabs | 1 tab | 2 tabs/day |
| 9-14 years | 3 tabs | 3 tabs | 1½ tabs | 4 tabs/day |
| ≥15 years | 4 tabs | 4 tabs | 2 tabs | 6 tabs/day |
Primaquine 0.25 mg/kg/day × 14 days (to eradicate liver hypnozoites)
- Contraindicated in infants, pregnancy, and G6PD deficiency - always test G6PD first
- Park's Textbook of Preventive and Social Medicine, p. 308
Harriet Lane (chloroquine-sensitive): Infant/child: 10 mg/kg/dose (max 600 mg) × 1, then 5 mg/kg/dose (max 300 mg) at 6, 24, and 48 h after initial dose. - Harriet Lane Handbook 23rd ed., p. 5948
3. P. malariae
Treat with chloroquine alone (same as vivax above) - no primaquine needed (no liver hypnozoites).
4. Severe / Complicated Malaria
IV/IM artesunate is first-line for all ages.
| Drug | Pediatric Dose | Notes |
|---|---|---|
| IV/IM Artesunate (preferred) | 2.4 mg/kg at 0, 12, 24 h, then once daily | Same mg/kg dose as adults; first-line WHO recommendation |
| IM Artemether (if artesunate unavailable) | 3.2 mg/kg IM loading dose, then 1.6 mg/kg/day | |
| IV Quinine (if artesunate/artemether unavailable) | 20 mg/kg IV over 4 h (loading), then 10 mg/kg every 8 h; infusion rate ≤5 mg/kg/h | Cardiac monitoring required; hypoglycemia risk |
Pre-referral (when parenteral not possible):
- Children <6 years: rectal artesunate 10 mg/kg, then transfer immediately
- Rectal artesunate is not recommended for older children/adults
After parenteral treatment (once oral tolerated):
-
Complete a full 3-day course of oral ACT (area-specific)
-
OR oral quinine + clindamycin × 7 days (in children <8 yr)
-
Park's Textbook, p. 311; Goldman-Cecil Medicine, p. 1068; WHO guidelines
Key Pediatric Caveats
| Issue | Rule |
|---|---|
| Doxycycline | Avoid in children <8 years (dental/bone toxicity); use clindamycin instead |
| Primaquine / Tafenoquine | Test G6PD first - can cause hemolytic anemia; contraindicated in infants |
| Atovaquone-proguanil | Not for <5 kg |
| Artemether-lumefantrine | Not for <5 kg |
| Arteether (IM) | Adults only - not recommended for children |
| Mefloquine | Caution in children <10 kg; avoid if seizure history |
| Pediatric doses | Should never exceed the adult dose |
| ACT in NE India (artemisinin partial resistance) | Use artemether-lumefantrine (ACT-AL) instead of ACT-SP |
Resistance Considerations (2025-2026)
Artemisinin partial resistance (kelch13 mutations) is documented across Southeast Asia (Myanmar, Cambodia, Vietnam, Thailand) and increasingly in East Africa. For children returning from these areas, the WHO 2025 malaria guidelines recommend considering dihydroartemisinin-piperaquine (DHA/PPQ) or atovaquone-proguanil as follow-up oral treatment after IV artesunate. Always verify regional resistance data before prescribing.
A 2025 systematic review (PMID 41350822) specifically addresses management in neonates, a group with limited evidence where individualized specialist guidance is essential.
Sources: Harriet Lane Handbook 23rd ed.; Tintinalli's Emergency Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics; Goldman-Cecil Medicine; Park's Textbook of Preventive and Social Medicine; WHO Guidelines for Malaria 2025
This is a shared conversation. Sign in to Orris to start your own chat.